These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 19018083)

  • 1. [18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group.
    Oechsle K; Hartmann M; Brenner W; Venz S; Weissbach L; Franzius C; Kliesch S; Mueller S; Krege S; Heicappell R; Bares R; Bokemeyer C; de Wit M;
    J Clin Oncol; 2008 Dec; 26(36):5930-5. PubMed ID: 19018083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma.
    Kollmannsberger C; Oechsle K; Dohmen BM; Pfannenberg A; Bares R; Claussen CD; Kanz L; Bokemeyer C
    Cancer; 2002 May; 94(9):2353-62. PubMed ID: 12015760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes of patients with nonseminomatous germ cell tumours and negative postchemotherapy positron emission tomography.
    Buchler T; Simonova K; Fencl P; Jarkovsky J; Abrahamova J
    Cancer Invest; 2012 Jul; 30(6):487-92. PubMed ID: 22506657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Early prediction of treatment response to high-dose chemotherapy in patients with relapsed germ cell tumors using [18F]FDG-PET, CT or MRI, and tumor marker].
    Pfannenberg AC; Oechsle K; Kollmannsberger C; Dohmen BM; Bokemeyer C; Bares R; Vontheim R; Claussen CD
    Rofo; 2004 Jan; 176(1):76-84. PubMed ID: 14712410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours.
    Spermon JR; De Geus-Oei LF; Kiemeney LA; Witjes JA; Oyen WJ
    BJU Int; 2002 Apr; 89(6):549-56. PubMed ID: 11942962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic value of 18F-FDG positron emission tomography for detection and treatment control of malignant germ cell tumors.
    Tsatalpas P; Beuthien-Baumann B; Kropp J; Manseck A; Tiepolt C; Hakenberg OW; Burchert W; Franke WG; Wirth MP
    Urol Int; 2002; 68(3):157-63. PubMed ID: 11919460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [18F]-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trial.
    de Wit M; Brenner W; Hartmann M; Kotzerke J; Hellwig D; Lehmann J; Franzius C; Kliesch S; Schlemmer M; Tatsch K; Heicappell R; Geworski L; Amthauer H; Dohmen BM; Schirrmeister H; Cremerius U; Bokemeyer C; Bares R
    Ann Oncol; 2008 Sep; 19(9):1619-23. PubMed ID: 18453520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Positron emission tomography with [18 F]-2-fluoro-2-deoxy-D-glucose (18FDG-PET) in diagnosis of retroperitoneal lymph node metastases of testicular tumors].
    Müller-Mattheis V; Reinhardt M; Gerharz CD; Fürst G; Vosberg H; Müller-Gärtner HW; Ackermann R
    Urologe A; 1998 Nov; 37(6):609-20. PubMed ID: 9887489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse.
    Hain SF; O'Doherty MJ; Timothy AR; Leslie MD; Harper PG; Huddart RA
    Br J Cancer; 2000 Oct; 83(7):863-9. PubMed ID: 10970686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of [(18)F] FDG-PET, CT/MRI and tumor marker kinetics in the evaluation of post chemotherapy residual masses in metastatic germ cell tumors--prospects for management.
    Pfannenberg AC; Oechsle K; Bokemeyer C; Kollmannsberger C; Dohmen BM; Bares R; Hartmann JT; Vonthein R; Claussen CD
    World J Urol; 2004 Jun; 22(2):132-9. PubMed ID: 14735310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours.
    Lassen U; Daugaard G; Eigtved A; Højgaard L; Damgaard K; Rørth M
    Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):396-402. PubMed ID: 12634968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of
    Dolci C; Ceppi L; Guerra L; Crivellaro C; Lamanna M; Adorni M; Elisei F; Bonazzi CM; Sina F; Fruscio R; Messa C
    Int J Gynecol Cancer; 2019 Oct; 29(8):1298-1303. PubMed ID: 31366569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Positron emission tomography in the diagnosis and monitoring of patients with nonseminomatous germ cell tumours].
    Büchler T; Simonová K; Fencl P; Abrahámová J
    Klin Onkol; 2011; 24(6):413-7. PubMed ID: 22257229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses.
    Oldenburg J; Alfsen GC; Lien HH; Aass N; Waehre H; Fossa SD
    J Clin Oncol; 2003 Sep; 21(17):3310-7. PubMed ID: 12947067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-fluorodeoxyglucose positron emission tomography in evaluation of germ cell tumor after chemotherapy.
    Johns Putra L; Lawrentschuk N; Ballok Z; Hannah A; Poon A; Tauro A; Davis ID; Hicks RJ; Bolton DM; Scott AM
    Urology; 2004 Dec; 64(6):1202-7. PubMed ID: 15596197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Positron emission tomography in germ cell tumors in men : Possibilities and limitations].
    Schriefer P; Hartmann M; Oechsle K; Meyer CP; Klutmann S; Fisch M; Bokemeyer C; Oing C
    Urologe A; 2019 Apr; 58(4):418-423. PubMed ID: 30374517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma.
    De Santis M; Bokemeyer C; Becherer A; Stoiber F; Oechsle K; Kletter K; Dohmen BM; Dittrich C; Pont J
    J Clin Oncol; 2001 Sep; 19(17):3740-4. PubMed ID: 11533096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma.
    Hinz S; Schrader M; Kempkensteffen C; Bares R; Brenner W; Krege S; Franzius C; Kliesch S; Heicappel R; Miller K; de Wit M
    J Urol; 2008 Mar; 179(3):936-40; discussion 940. PubMed ID: 18207171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 18F-fluoro-2-deoxyglucose-positron emission tomography in the evaluation of nonseminomatous germ cell tumours at relapse.
    Sanchez D; Zudaire JJ; Fernandez JM; Lopez J; Arocena J; Sanz G; Gimenez M; Rosell D; Robles JE; Berian JM
    BJU Int; 2002 Jun; 89(9):912-6. PubMed ID: 12010239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial.
    De Santis M; Becherer A; Bokemeyer C; Stoiber F; Oechsle K; Sellner F; Lang A; Kletter K; Dohmen BM; Dittrich C; Pont J
    J Clin Oncol; 2004 Mar; 22(6):1034-9. PubMed ID: 15020605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.